Core Insights - ImmuneOnco Biopharmaceuticals announced preliminary safety and efficacy data for IMM2510/AXN-2510 in front-line NSCLC patients, showing promising results that support further clinical development [1][4] Efficacy Data - As of July 1, 2025, 33 patients were dosed at 10 mg/kg, with 62% of efficacy evaluable patients showing partial responses, including 80% in squamous NSCLC and 46% in non-squamous NSCLC [2] - The majority of efficacy evaluable patients had only one tumor assessment at the data cut-off [2] Safety Profile - The safety profile of '2510 supports further clinical development, with no dose-limiting toxicities observed in 33 safety evaluable patients [3] - There were no treatment-related adverse events leading to dose reduction or death, with only one event leading to drug discontinuation [3] - Common Grade 3+ treatment-related adverse events were hematologic, while adverse events typically associated with VEGF inhibition and immune-related events were uncommon and generally low-grade [3] Future Developments - ImmuneOnco plans to present updated safety and efficacy data at a future medical conference [1] - The data from this study paves the way for advancement into Phase 3 clinical studies [4] - Instil Bio anticipates further public updates from ImmuneOnco and the initiation of a US Phase 1 clinical trial by the end of the year [4] Product Information - IMM2510/AXN-2510 is a PD-L1xVEGF bispecific antibody designed for the treatment of multiple solid tumors, differentiated by its VEGF trap and enhanced antibody-dependent cellular cytotoxicity [5] Company Background - ImmuneOnco is a clinical-stage biotech company focused on developing biologics for cancer and other diseases, with multiple assets in development [6] - Instil Bio is also a clinical-stage biopharmaceutical company with a focus on novel therapies [7]